The possibility of definitive chemoradiotherapy for patients with resectable stage IIIA N2 non-small cell lung cancer

Tomonari Sasaki, Takashi Seto, Ohga Saiji, Tadamasa Yoshitake

研究成果: ジャーナルへの寄稿評論記事

抄録

The 2014 edition of the clinical guidelines for lung cancer in Japan included the following description, "Surgical resection may be considered after induction therapy for patients with clinical N2-IIIA non-small cell lung cancer (NSCLC)." However, the definition of resectable lung cancer may vary from institution to institution, and preoperative chemotherapy regimens and radiation doses have not been standardized. Moreover, largescale clinical trials including INT0139, EORTC08941 could not prove the significance of surgery in combination with preoperative treatment for patients with stage III NSCLC. Recently, chemoradiotherapy has been associated with improved clinical outcomes in patients with unresectable stage III NSCLC. Some phase II trials have shown 2-year overall survival rates of 40-80%; thus, with appropriate patient selection, some patients with resectable stage III NSCLC may be completely cured with chemoradiotherapy. The West Japan Oncology Group, which has been developing a new treatment strategy for patients with unresectable stage III NSCLC, reported the first results of WJOG5008L at ASCO2015. We review the possible use of chemoradiotherapy in the treatment of patients with resectable stage III NSCLC with reference to the first results from WJOG5008L.

元の言語英語
ページ(範囲)982-985
ページ数4
ジャーナルJapanese Journal of Lung Cancer
55
発行部数6
DOI
出版物ステータス出版済み - 10 20 2015

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Japan
Therapeutics
Patient Selection
Survival Rate
Clinical Trials
Guidelines
Radiation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

これを引用

The possibility of definitive chemoradiotherapy for patients with resectable stage IIIA N2 non-small cell lung cancer. / Sasaki, Tomonari; Seto, Takashi; Saiji, Ohga; Yoshitake, Tadamasa.

:: Japanese Journal of Lung Cancer, 巻 55, 番号 6, 20.10.2015, p. 982-985.

研究成果: ジャーナルへの寄稿評論記事

@article{0fa1f4a109724fe7ac4e4cc551493e19,
title = "The possibility of definitive chemoradiotherapy for patients with resectable stage IIIA N2 non-small cell lung cancer",
abstract = "The 2014 edition of the clinical guidelines for lung cancer in Japan included the following description, {"}Surgical resection may be considered after induction therapy for patients with clinical N2-IIIA non-small cell lung cancer (NSCLC).{"} However, the definition of resectable lung cancer may vary from institution to institution, and preoperative chemotherapy regimens and radiation doses have not been standardized. Moreover, largescale clinical trials including INT0139, EORTC08941 could not prove the significance of surgery in combination with preoperative treatment for patients with stage III NSCLC. Recently, chemoradiotherapy has been associated with improved clinical outcomes in patients with unresectable stage III NSCLC. Some phase II trials have shown 2-year overall survival rates of 40-80{\%}; thus, with appropriate patient selection, some patients with resectable stage III NSCLC may be completely cured with chemoradiotherapy. The West Japan Oncology Group, which has been developing a new treatment strategy for patients with unresectable stage III NSCLC, reported the first results of WJOG5008L at ASCO2015. We review the possible use of chemoradiotherapy in the treatment of patients with resectable stage III NSCLC with reference to the first results from WJOG5008L.",
author = "Tomonari Sasaki and Takashi Seto and Ohga Saiji and Tadamasa Yoshitake",
year = "2015",
month = "10",
day = "20",
doi = "10.2482/haigan.55.982",
language = "English",
volume = "55",
pages = "982--985",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "6",

}

TY - JOUR

T1 - The possibility of definitive chemoradiotherapy for patients with resectable stage IIIA N2 non-small cell lung cancer

AU - Sasaki, Tomonari

AU - Seto, Takashi

AU - Saiji, Ohga

AU - Yoshitake, Tadamasa

PY - 2015/10/20

Y1 - 2015/10/20

N2 - The 2014 edition of the clinical guidelines for lung cancer in Japan included the following description, "Surgical resection may be considered after induction therapy for patients with clinical N2-IIIA non-small cell lung cancer (NSCLC)." However, the definition of resectable lung cancer may vary from institution to institution, and preoperative chemotherapy regimens and radiation doses have not been standardized. Moreover, largescale clinical trials including INT0139, EORTC08941 could not prove the significance of surgery in combination with preoperative treatment for patients with stage III NSCLC. Recently, chemoradiotherapy has been associated with improved clinical outcomes in patients with unresectable stage III NSCLC. Some phase II trials have shown 2-year overall survival rates of 40-80%; thus, with appropriate patient selection, some patients with resectable stage III NSCLC may be completely cured with chemoradiotherapy. The West Japan Oncology Group, which has been developing a new treatment strategy for patients with unresectable stage III NSCLC, reported the first results of WJOG5008L at ASCO2015. We review the possible use of chemoradiotherapy in the treatment of patients with resectable stage III NSCLC with reference to the first results from WJOG5008L.

AB - The 2014 edition of the clinical guidelines for lung cancer in Japan included the following description, "Surgical resection may be considered after induction therapy for patients with clinical N2-IIIA non-small cell lung cancer (NSCLC)." However, the definition of resectable lung cancer may vary from institution to institution, and preoperative chemotherapy regimens and radiation doses have not been standardized. Moreover, largescale clinical trials including INT0139, EORTC08941 could not prove the significance of surgery in combination with preoperative treatment for patients with stage III NSCLC. Recently, chemoradiotherapy has been associated with improved clinical outcomes in patients with unresectable stage III NSCLC. Some phase II trials have shown 2-year overall survival rates of 40-80%; thus, with appropriate patient selection, some patients with resectable stage III NSCLC may be completely cured with chemoradiotherapy. The West Japan Oncology Group, which has been developing a new treatment strategy for patients with unresectable stage III NSCLC, reported the first results of WJOG5008L at ASCO2015. We review the possible use of chemoradiotherapy in the treatment of patients with resectable stage III NSCLC with reference to the first results from WJOG5008L.

UR - http://www.scopus.com/inward/record.url?scp=84954150262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954150262&partnerID=8YFLogxK

U2 - 10.2482/haigan.55.982

DO - 10.2482/haigan.55.982

M3 - Review article

VL - 55

SP - 982

EP - 985

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 6

ER -